Tikun Olam is the largest government approved producer of medical cannabis in the State of Israel. Through
our exclusive partnership, MedReleaf is growing many of Tikun Olam’s proprietary cannabis varieties in
Canada. These varieties include Eran Almog, Midnight, and a non-psychoactive
variety high in cannabidiol(CBD) content with only trace amounts of tetrahydrocannabinol (THC), Avidekel.
Tikun Olam is a leader in innovation, spearheading numerous studies which examine the effects that their proprietary strains have on a variety of diseases and conditions. With more than 10,000 treated patients, Tikun Olam has what is believed to be one of, if not the most, extensive patient treatment experience database in the field of medical cannabis anywhere in the world. MedReleaf has exclusive access to this important patient and treatment data, allowing us to recommend to our patients the variety(s) that would be most effective for their particular needs.
Ehave Inc. (OTCQB: EHVVF) is a healthcare company dedicated to empowering the mental health community with next-generation digital solutions. Ehave and MedReleaf have partnered to develop a branded app utilizing the Ehave Connect mental health informatics platform to advance the study and therapeutic use of medical cannabis. Ehave Connect enables developers, and ultimately prescribers, of medical cannabis to design and monitor treatment plans, track patient compliance, and verify treatment outcomes in a reliable and objective manner. Together, Ehave and MedReleaf seek to validate and optimize the use of MedReleaf’s medical cannabis products as therapeutic treatments for various mental health conditions. Ultimately, it is anticipated that the MedReleaf App based on the Ehave Connect platform can be used to monitor every step of the medical cannabis treatment life cycle, from diagnosis and treatment planning to medication adherence and outcomes verification.